Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL

The goal of this clinical study is to evaluate the efficacy and safety of sintilimab combined with rituximab followed by R-CHOP regimen in treatment-naïve patients with primary mediastinal diffuse large B-cell lymphoma. The main questions it aims to answer are: 1. Objective response rate of sintilimab combined with rituximab 2. Objective response rate after R-CHOP regimen

Trial Details

NCT ID

NCT06742502

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Sintlimab+Rituximab follwed by R-CHOP(Cyclophosphamide, doxorubicin, vincristine, prednisone)

Locations (sample)

Fuzhou, Fujian, China|26.06139,119.30611
Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Voluntary participation in clinical study and fully understand, informed consent and sign informed consent form (ICF);
Age ≥ 18 years and ≤ 75 years at the time of signing the ICF.
treatment-naïve, no anti-lymphoma therapy.
Primary mediastinal DLBCL was confirmed histopathologically at the study site.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →